T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
1226
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $25.5M | ﹤0.01% |
966,011
-90,776
| -9% | -$7.02M |
|
1227
Columbia Financial
CLBK
$1.21B
| $25.5M | ﹤0.01% |
1,220,894
-789
| -0.1% | -$15.3K |
|
1228
LKQ Corp
LKQ
$6.41B
| $25.2M | ﹤0.01% |
419,930
-36,053
| -8% | -$2.03M |
|
1229
Vir Biotechnology
VIR
$1.52B
| $25M | ﹤0.01% |
597,433
+560,914
| +1,536% | +$22M |
|
1230
DigitalOcean
DOCN
$15.1B
| $25M | ﹤0.01% |
311,360
+307,197
| +7,379% | +$28.8M |
|
|
K
1231
DELISTED
Kellanova
K
| $24.7M | ﹤0.01% |
409,093
-11,188
| -3% | -$660K |
|
1232
Applovin
APP
$107B
| $24.7M | ﹤0.01% |
262,163
+256,063
| +4,198% | +$23.8M |
|
|
CTRA
1233
DELISTED
Coterra Energy
CTRA
| $24.7M | ﹤0.01% |
1,299,277
+606,150
| +87% | +$12.6M |
|
1234
Viatris
VTRS
$18.5B
| $24.5M | ﹤0.01% |
1,812,784
-78,270
| -4% | -$1.05M |
|
|
AKRO
1235
DELISTED
Akero Therapeutics
AKRO
| $24.5M | ﹤0.01% |
1,159,530
+7,931
| +0.7% | +$176K |
|
1236
Boston Properties
BXP
$10.9B
| $24.5M | ﹤0.01% |
212,763
-5,748
| -3% | -$662K |
|
1237
Eastman Chemical
EMN
$8.43B
| $24.2M | ﹤0.01% |
200,369
-10,294
| -5% | -$1.14M |
|
1238
Carnival Corporation Ltd
CCL
$38.9B
| $24.2M | ﹤0.01% |
1,203,631
-76,928
| -6% | -$1.65M |
|
1239
Academy Sports + Outdoors
ASO
$2.98B
| $24.1M | ﹤0.01% |
548,454
+13,547
| +3% | +$588K |
|
1240
Bloomin' Brands
BLMN
$907M
| $24M | ﹤0.01% |
1,142,549
-191,159
| -14% | -$4.03M |
|
1241
Evergy
EVRG
$19.3B
| $23.9M | ﹤0.01% |
348,921
-1,201,457
| -77% | -$78.1M |
|
|
FOLD
1242
DELISTED
Amicus Therapeutics
FOLD
| $23.9M | ﹤0.01% |
2,065,142
-712,106
| -26% | -$7.94M |
|
|
SMAR
1243
DELISTED
Smartsheet Inc.
SMAR
| $23.7M | ﹤0.01% |
306,263
-2,177
| -0.7% | -$152K |
|
1244
iShares Core S&P 500 ETF
IVV
$908B
| $23.4M | ﹤0.01% |
49,038
+10,123
| +26% | +$4.67M |
|
|
CNTA
1245
DELISTED
Centessa Pharmaceuticals
CNTA
| $23.4M | ﹤0.01% |
2,076,770
+58,897
| +3% | +$792K |
|
1246
Alarm.com
ALRM
$2.72B
| $23.3M | ﹤0.01% |
275,142
-11,968
| -4% | -$979K |
|
|
IPG
1247
DELISTED
Interpublic Group of Companies
IPG
| $23.2M | ﹤0.01% |
620,592
-2,479
| -0.4% | -$90.1K |
|
1248
Rapid Micro Biosystems
RPID
$85.3M
| $23.2M | ﹤0.01% |
2,199,746
+343,704
| +19% | +$5.37M |
|
1249
Service Corp International
SCI
$11.5B
| $23.1M | ﹤0.01% |
324,781
+954
| +0.3% | +$63.4K |
|
1250
Advance Auto Parts
AAP
$3.4B
| $23M | ﹤0.01% |
95,822
-7,619
| -7% | -$1.74M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.